Alkermes (ALKS) Competitors

$38.91 +0.62 (+1.62%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$39.00 +0.09 (+0.24%)

As of 07:49 AM Eastern

ALKS vs. ABEO, MEDP, OMCL, AMN, and INCY

Should you buy Alkermes stock or one of its competitors? MarketBeat compares Alkermes with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alkermes include Abeona Therapeutics (ABEO), Medpace (MEDP), Omnicell (OMCL), AMN Healthcare Services (AMN), and Incyte (INCY). These companies are all part of the "medical" sector.

How does Alkermes compare to Abeona Therapeutics?

Alkermes (NASDAQ:ALKS) and Abeona Therapeutics (NASDAQ:ABEO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

Alkermes has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Abeona Therapeutics has a beta of 1.35, suggesting that its share price is 35% more volatile than the broader market.

Alkermes has higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	4.39	$241.66M	$0.90	43.23
Abeona Therapeutics	$5.82M	55.81	$71.18M	$1.03	5.54

Alkermes has a net margin of 9.78% compared to Abeona Therapeutics' net margin of 0.00%. Alkermes' return on equity of 9.26% beat Abeona Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	9.78%	9.26%	5.66%
Abeona Therapeutics	N/A	-60.65%	-40.78%

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 4.6% of Alkermes shares are owned by company insiders. Comparatively, 6.9% of Abeona Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Alkermes presently has a consensus target price of $45.40, suggesting a potential upside of 16.68%. Abeona Therapeutics has a consensus target price of $19.00, suggesting a potential upside of 232.75%. Given Abeona Therapeutics' higher probable upside, analysts plainly believe Abeona Therapeutics is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	0 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.76
Abeona Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Alkermes had 11 more articles in the media than Abeona Therapeutics. MarketBeat recorded 23 mentions for Alkermes and 12 mentions for Abeona Therapeutics. Abeona Therapeutics' average media sentiment score of 0.69 beat Alkermes' score of 0.50 indicating that Abeona Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abeona Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Alkermes beats Abeona Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Alkermes compare to Medpace?

Medpace (NASDAQ:MEDP) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Medpace has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, Alkermes has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

Medpace has higher revenue and earnings than Alkermes. Medpace is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.68B	4.52	$451.12M	$15.91	26.63
Alkermes	$1.48B	4.39	$241.66M	$0.90	43.23

In the previous week, Medpace had 9 more articles in the media than Alkermes. MarketBeat recorded 32 mentions for Medpace and 23 mentions for Alkermes. Alkermes' average media sentiment score of 0.50 beat Medpace's score of 0.21 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Medpace	4 Very Positive mention(s)	0 Positive mention(s)	26 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Alkermes	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Medpace currently has a consensus target price of $467.08, suggesting a potential upside of 10.22%. Alkermes has a consensus target price of $45.40, suggesting a potential upside of 16.68%. Given Alkermes' stronger consensus rating and higher possible upside, analysts plainly believe Alkermes is more favorable than Medpace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Alkermes	0 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.76

78.0% of Medpace shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 20.5% of Medpace shares are held by insiders. Comparatively, 4.6% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Medpace has a net margin of 17.19% compared to Alkermes' net margin of 9.78%. Medpace's return on equity of 120.89% beat Alkermes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medpace	17.19%	120.89%	24.79%
Alkermes	9.78%	9.26%	5.66%

Summary

Medpace beats Alkermes on 10 of the 17 factors compared between the two stocks.

How does Alkermes compare to Omnicell?

Alkermes (NASDAQ:ALKS) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

Alkermes currently has a consensus target price of $45.40, suggesting a potential upside of 16.68%. Omnicell has a consensus target price of $59.86, suggesting a potential upside of 38.65%. Given Omnicell's stronger consensus rating and higher probable upside, analysts clearly believe Omnicell is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	0 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.76
Omnicell	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

Alkermes has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market. Comparatively, Omnicell has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Alkermes has a net margin of 9.78% compared to Omnicell's net margin of 1.67%. Alkermes' return on equity of 9.26% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	9.78%	9.26%	5.66%
Omnicell	1.67%	4.00%	2.46%

95.2% of Alkermes shares are held by institutional investors. Comparatively, 97.7% of Omnicell shares are held by institutional investors. 4.6% of Alkermes shares are held by insiders. Comparatively, 2.9% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Alkermes has higher revenue and earnings than Omnicell. Alkermes is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	4.39	$241.66M	$0.90	43.23
Omnicell	$1.18B	1.66	$2.05M	$0.44	98.11

In the previous week, Alkermes had 3 more articles in the media than Omnicell. MarketBeat recorded 23 mentions for Alkermes and 20 mentions for Omnicell. Omnicell's average media sentiment score of 0.76 beat Alkermes' score of 0.50 indicating that Omnicell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omnicell	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Alkermes beats Omnicell on 10 of the 16 factors compared between the two stocks.

How does Alkermes compare to AMN Healthcare Services?

Alkermes (NASDAQ:ALKS) and AMN Healthcare Services (NYSE:AMN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

Alkermes has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

Alkermes presently has a consensus price target of $45.40, suggesting a potential upside of 16.68%. AMN Healthcare Services has a consensus price target of $25.29, suggesting a potential downside of 17.97%. Given Alkermes' stronger consensus rating and higher possible upside, research analysts plainly believe Alkermes is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	0 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.76
AMN Healthcare Services	2 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.44

Alkermes has higher earnings, but lower revenue than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	4.39	$241.66M	$0.90	43.23
AMN Healthcare Services	$2.73B	0.44	-$95.70M	-$0.87	N/A

In the previous week, Alkermes had 2 more articles in the media than AMN Healthcare Services. MarketBeat recorded 23 mentions for Alkermes and 21 mentions for AMN Healthcare Services. AMN Healthcare Services' average media sentiment score of 0.56 beat Alkermes' score of 0.50 indicating that AMN Healthcare Services is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AMN Healthcare Services	4 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Alkermes has a net margin of 9.78% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Alkermes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	9.78%	9.26%	5.66%
AMN Healthcare Services	-0.95%	18.01%	5.19%

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are owned by institutional investors. 4.6% of Alkermes shares are owned by company insiders. Comparatively, 1.1% of AMN Healthcare Services shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Alkermes beats AMN Healthcare Services on 12 of the 16 factors compared between the two stocks.

How does Alkermes compare to Incyte?

Alkermes (NASDAQ:ALKS) and Incyte (NASDAQ:INCY) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

Alkermes has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market. Comparatively, Incyte has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market.

Alkermes presently has a consensus price target of $45.40, suggesting a potential upside of 16.68%. Incyte has a consensus price target of $104.26, suggesting a potential upside of 5.51%. Given Alkermes' stronger consensus rating and higher possible upside, research analysts plainly believe Alkermes is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	0 Sell rating(s)	5 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.76
Incyte	1 Sell rating(s)	10 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.43

Incyte has higher revenue and earnings than Alkermes. Incyte is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	4.39	$241.66M	$0.90	43.23
Incyte	$5.14B	3.84	$1.29B	$7.08	13.96

In the previous week, Alkermes had 11 more articles in the media than Incyte. MarketBeat recorded 23 mentions for Alkermes and 12 mentions for Incyte. Incyte's average media sentiment score of 0.78 beat Alkermes' score of 0.50 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alkermes	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Incyte has a net margin of 26.71% compared to Alkermes' net margin of 9.78%. Incyte's return on equity of 26.66% beat Alkermes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	9.78%	9.26%	5.66%
Incyte	26.71%	26.66%	19.77%

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 4.6% of Alkermes shares are owned by company insiders. Comparatively, 16.2% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Incyte beats Alkermes on 10 of the 17 factors compared between the two stocks.

Get Alkermes News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALKS vs. The Competition

Export

Metric	Alkermes	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.38B	$3.42B	$6.31B	$12.28B
Dividend Yield	N/A	2.31%	2.79%	5.30%
P/E Ratio	43.23	18.67	21.03	25.58
Price / Sales	4.39	301.04	552.34	78.22
Price / Cash	22.87	122.51	42.94	55.34
Price / Book	3.70	6.75	9.83	6.66
Net Income	$241.66M	$24.11M	$3.55B	$333.63M
7 Day Performance	9.92%	-0.53%	-0.52%	-0.12%
1 Month Performance	14.88%	0.34%	1.20%	3.93%
1 Year Performance	27.07%	78.62%	41.25%	36.07%

Alkermes Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALKS Alkermes	2.5546 of 5 stars	$38.91 +1.6%	$45.40 +16.7%	+26.2%	$6.38B	$1.48B	43.23	2,050	Trending News Analyst Downgrade Analyst Revision
ABEO Abeona Therapeutics	2.9892 of 5 stars	$5.86 -0.7%	$19.00 +224.2%	+1.4%	$335.61M	$5.82M	5.69	90	News Coverage Earnings Report
MEDP Medpace	3.1285 of 5 stars	$417.29 -1.6%	$467.08 +11.9%	+36.6%	$12.11B	$2.53B	26.23	6,200	Trending News
OMCL Omnicell	3.8263 of 5 stars	$43.30 -1.2%	$59.86 +38.2%	+54.2%	$1.99B	$1.18B	98.41	3,580	Trending News Analyst Revision
AMN AMN Healthcare Services	1.7495 of 5 stars	$30.43 +5.0%	$23.50 -22.8%	+41.3%	$1.12B	$2.73B	N/A	2,664	Earnings Report Analyst Forecast High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALKS) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alkermes (ALKS) Competitors

ALKS vs. ABEO, MEDP, OMCL, AMN, and INCY

How does Alkermes compare to Abeona Therapeutics?

Summary

How does Alkermes compare to Medpace?

Summary

How does Alkermes compare to Omnicell?

Summary

How does Alkermes compare to AMN Healthcare Services?

Summary

How does Alkermes compare to Incyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALKS vs. The Competition

Alkermes Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alkermes (ALKS) Competitors

ALKS vs. ABEO, MEDP, OMCL, AMN, and INCY

How does Alkermes compare to Abeona Therapeutics?

Which has more volatility & risk, ALKS or ABEO?

Which has higher earnings & valuation, ALKS or ABEO?

Is ALKS or ABEO more profitable?

Do insiders and institutionals have more ownership in ALKS or ABEO?

Do analysts recommend ALKS or ABEO?

Does the media favor ALKS or ABEO?

Summary

How does Alkermes compare to Medpace?

Which has more risk and volatility, MEDP or ALKS?

Which has better earnings & valuation, MEDP or ALKS?

Does the media refer more to MEDP or ALKS?

Do analysts rate MEDP or ALKS?

Do institutionals and insiders have more ownership in MEDP or ALKS?

Is MEDP or ALKS more profitable?

Summary

How does Alkermes compare to Omnicell?

Do analysts rate ALKS or OMCL?

Which has more risk & volatility, ALKS or OMCL?

Is ALKS or OMCL more profitable?

Do insiders & institutionals hold more shares of ALKS or OMCL?

Which has preferable valuation and earnings, ALKS or OMCL?

Does the media refer more to ALKS or OMCL?

Summary

How does Alkermes compare to AMN Healthcare Services?

Which has more risk and volatility, ALKS or AMN?

Do analysts rate ALKS or AMN?

Which has better earnings & valuation, ALKS or AMN?

Does the media prefer ALKS or AMN?

Is ALKS or AMN more profitable?

Do institutionals and insiders hold more shares of ALKS or AMN?

Summary

How does Alkermes compare to Incyte?

Which has more risk and volatility, ALKS or INCY?

Do analysts rate ALKS or INCY?

Which has better earnings & valuation, ALKS or INCY?

Does the media prefer ALKS or INCY?

Is ALKS or INCY more profitable?

Do institutionals and insiders hold more shares of ALKS or INCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALKS vs. The Competition

Alkermes Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools